Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery
Launched by SYKEHUSET I VESTFOLD HF · Oct 1, 2007
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are planned for open, elective abdominal aortic aneurysm surgery.
- • ASA group 1-4.
- Exclusion Criteria:
- • Patients below 18 years.
- • Patients who are included in other pharmaceutical studies.
- • Opioids-, benzodiazepins-, antiepileptic drugs-, alcohol- and α2-agonists abuse.
- • Pregnant and breastfeeding women.
- • Patients with familiar history of malignant hyperthermia.
- • Patients with known hypersensitivity for opioids, propofol or volative anaesthetics.
- • Patients with considerable arrythmia (atrial fibrillation /atrial flutter is acceptable). Uncontrolled hypertension, serious psychiatric disease.
- • Patients with unstable angina pectoris or myocardial infarction last month before inclusion.
- • Acute abdominal aortic surgery. Acute dissection or rupture.
- • Planned laparoscopic abdominal aortic aneurysm surgery.
About Sykehuset I Vestfold Hf
Sykehuset i Vestfold HF is a leading healthcare institution located in Vestfold, Norway, dedicated to providing high-quality medical care and advancing clinical research. As a prominent clinical trial sponsor, the organization is committed to enhancing patient outcomes through innovative research initiatives and collaboration with various stakeholders in the medical and scientific communities. With a focus on ethical standards and regulatory compliance, Sykehuset i Vestfold HF aims to contribute to the development of new therapies and treatment protocols, ensuring that its research efforts are aligned with the needs of patients and the broader healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tonsberg, , Norway
Patients applied
Trial Officials
Espen Lindholm, MD
Study Director
Sykehuset i Vestfold HF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials